NCM
AZN icon

Northside Capital Management’s AstraZeneca AZN Stock Holding History

Northside Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,600
Closed -$349K – 64
2017
Q1 		$349K Buy
+5,600
New +$326K 0.1% 105

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Northside Capital Management's AZN Position: Q2 2017 in Review

Northside Capital Management sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 5,600 shares — an estimated $349K sold.

Northside Capital Management first reported a position in AZN in Q1 2017 and held it in 1 quarter. The position peaked at $349K in Q1 2017. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

  • Northside Capital Management reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
  • Northside Capital Management sold 5,600 AstraZeneca shares in Q2 2017, an estimated $349K.
  • Northside Capital Management first reported a position in AstraZeneca in Q1 2017 and held it in 1 quarter.
  • Northside Capital Management's AstraZeneca position peaked at $349K in Q1 2017.
  • 466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Northside Capital Management's 13F filing for Q2 2017, filed 27 Jul 2017.